Frankfurt - Delayed Quote EUR
Paradigm Biopharmaceuticals Limited (P86.F)
0.1690
+0.0160
+(10.46%)
At close: 3:29:01 PM GMT+2
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC | Founder, MD & Executive Chairman | 563.77k | -- | 1959 |
| Dr. Donna L. Skerrett M.D., MS | Chief Medical Officer | 615.87k | -- | 1957 |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | Company Secretary & CFO | -- | -- | -- |
| Dr. Ravi Krishnan | Chief Scientific Officer | -- | -- | -- |
| Mr. Simon White | Director of Investor Relations | -- | -- | -- |
| Dr. Michael Imperiale | Global Head of Drug Safety & MPS | -- | -- | -- |
| Ms. Beverley Huttmann | Commercial Head | -- | -- | -- |
| Ms. Michelle Coffey | Global Head of Regulatory Affairs | -- | -- | -- |
| Dr. Mukesh Ahuja | Global Clinical Head of OA | -- | -- | -- |
Paradigm Biopharmaceuticals Limited
500 Collins Street
Level 15
Melbourne, VIC 3000
Australia
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Corporate Governance
Paradigm Biopharmaceuticals Limited’s ISS Governance QualityScore as of May 1, 2025 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 1; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
July 29, 2025 at 10:59 AM UTC - August 4, 2025 at 12:00 PM UTC
Paradigm Biopharmaceuticals Limited Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
NDTP NDT Pharmaceuticals Inc.
0.0905
0.00%
NBCO Neon Bloom, Inc.
0.0121
-5.47%
YECO EV Biologics, Inc.
0.0870
0.00%
STMM Stemcell Holdings, Inc.
0.0600
0.00%
TGRP TRON Group Inc.
0.0300
0.00%
PKTX ProtoKinetix, Incorporated
0.0100
+14.94%
MRZM Marizyme, Inc.
0.0003
0.00%
INTI Inhibitor Therapeutics, Inc.
0.0500
0.00%
SXTPW 60 Degrees Pharmaceuticals, Inc.
0.0570
+3.45%
EMMA Emmaus Life Sciences, Inc.
0.0165
0.00%